Figure 2 | Scientific Reports

Figure 2

From: A Metabolomics Pilot Study on Desmoid Tumors and Novel Drug Candidates

Figure 2

The unsupervised multivariate analysis (PCA) of desmoid, normal, and unaffected cell lines in the presence of Dasatinib (A) and FAK Inhibitor 14 (B). The PCA in the presence of Dasatinib [6 components, R2X = 0.99, Q2 (cum) = 0.92]. The PCA in the presence of FAK Inhibitor 14 [7 components, R2X = 0.99, Q2 (cum) = 0.94].

Back to article page